NeuroOne Medical Expects Product Revenue Of $8M-$10M In Fiscal Year 2025, Representing An Increase Of Between 132% And 190% When Compared To Product Revenue Of $3.5M In Fiscal Year 2024

+0.95%

NeuroOne Medical Technologies Corporation

NMTC

1.05

+0.95%

Expects product gross margin to range between 47% and 51% in fiscal year 2025, compared to product gross margin of 31% in fiscal year 2024.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.